XKRX
048530
Market cap65mUSD
Oct 08, Last price
2,845.00KRW
1D
-1.39%
1Q
9.42%
Jan 2017
-81.41%
IPO
-80.84%
Name
iNtRON Biotechnology Inc
Chart & performance
P/E
—
P/S
15.31
EPS
—
Div yield, %
3.51%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
-33.88%
Revenues
5.74b
-10.56%
Net income
-9.26b
L+257.38%
CFO
-4.97b
L+3,492.31%
Dividend
Dec 29, 2025100 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
iNtRON Biotechnology, Inc. is a global developer of biopharmaceutical solutions focused on averting and remedying human ailments. Its development efforts encompass a range of bacteriophage and endoricin-based therapeutics. This company, which has its primary operations in Seongnam-si, South Korea, was established in 1999.
Key people
Seong Jun Yoon
President, Co-Chief Executive Officer, Director
Gyeong Won Yoon
Co-Chief Executive Officer, Vice President, Director · since 2021
Sang Hyeon Kang
Vice President, Director · since 2022
Su Yeon Jeon
Assistant Managing Director
Man Sun Park
Assistant Managing Director · since 2020
Jong Seong Yoon
Internal Auditor
Jae Gu Sul
Managing Director · since 2014
Myeong Hun Sung
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||